journal article·2022-01Open access

Double hit strategy using pH-sensitive liposomes containing doxorubicin and pheophorbide-a for combination tumor therapy

Eunyoung Park, Donghyun Lee, Yeeun Lee, Eunjin Jeong, Sehee Kim, Heebeom Koo

Abstract

For successful combination therapy using nanoparticles, stable loading and targeted delivery of different drugs are important. Herein, we prepared pH-sensitive liposomes with hydrophilic doxorubicin (Dox) in the core and hydrophobic pheophobide-a (Pba) in the lipid membrane (pH-lipo-Dox-Pba). The liposomes provided high drug accumulation in tumor tissue, with an enhanced permeability and retention (EPR) effect and enhanced binding to tumor cells by cyclic Arg-Gly-Asp peptide (cRGD). After cellular uptake, Dox was released in response to the endo-lysosomal acidic pH and moved into the nucleus, while Pba remained in the cytosol. Therefore, a double hit strategy composed of a simultaneous attack on nucleus and cytosol could be achieved by chemo- and photodynamic therapy. High tumor accumulation of pH-lipo-Dox-Pba was observed after intravenous injection into 4T1 tumor-bearing mice. Effective suppression of tumor growth in the same mouse model demonstrated a synergetic effect of combination therapy enabled by the double hit strategy using pH-lipo-Dox-Pba.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (29)

Show source-provided references
1. Kolesar · Am. J. Health Syst. Pharm. · 2021 · 78 · 99910.1093/ajhp/zxab084 ↗
2. Dusetzina · JAMA · 2021 · 325 · 52710.1001/jama.2020.25424 ↗
3. Vargason · Nat. Biomed. Eng. · 2021 · 5 · 95110.1038/s41551-021-00698-w ↗
4. Koo · Acc. Chem. Res. · 2011 · 44 · 101810.1021/ar2000138 ↗
5. Maeda · J. Control. Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
6. Greco · Adv. Drug Deliv. Rev. · 2009 · 61 · 120310.1016/j.addr.2009.05.006 ↗
7. Rawal · J. Control. Release · 2019 · 301 · 7610.1016/j.jconrel.2019.03.015 ↗
8. Barenholz · J. Control. Release · 2012 · 160 · 11710.1016/j.jconrel.2012.03.020 ↗
9. Liang · Adv. Mater. · 2018 · 30 · 170696310.1002/adma.201706963 ↗
10. Lee · Bioactive Mater. · 2022 · 8 · 2010.1016/j.bioactmat.2021.06.019 ↗
11. Ma · Pharm. Res. · 2018 · 35 · 5710.1007/s11095-017-2295-z ↗
12. Cui · Adv. Mater. Interfaces · 2020 · 7 · 200029210.1002/admi.202000292 ↗
13. Lovell · Chem. Rev. · 2010 · 110 · 283910.1021/cr900236h ↗
14. Rehman · Eur. J. Pharm. Biopharm. · 2018 · 133 · 33110.1016/j.ejpb.2018.11.001 ↗
15. Choi · Int. J. Pharm. · 2017 · 532 · 67710.1016/j.ijpharm.2017.03.007 ↗
16. Lee · Exp. Therapeut. Med. · 2018 · 15 · 4950
17. Bergstrand · Biophys. Chem. · 2003 · 104 · 36110.1016/S0301-4622(03)00011-5 ↗
18. Wang · Nanomed. Nanotechnol. Biol. Med. · 2012 · 8 · 19410.1016/j.nano.2011.06.006 ↗
19. Lu · Nanoscale · 2018 · 10 · 995710.1039/C8NR01184B ↗
20. Fleischmann · ACS Appl. Mater. Interfaces · 2020 · 12 · 3468910.1021/acsami.0c10057 ↗
21. Wu · Angew. Chem. Int. Ed. · 2021 · 60 · 1110410.1002/anie.202014162 ↗
22. Lee · ACS Appl. Mater. Interfaces · 2021 · 13 · 1081210.1021/acsami.1c02316 ↗
23. Jain · J. Nanopart. Res. · 2013 · 15
24. De Beer · Eur. J. Pharmacol. · 2001 · 415 · 110.1016/S0014-2999(01)00765-8 ↗
25. Horwitz · Ann. Oncol. · 1994 · 5 · S3
26. Park · J. Control. Release · 2006 · 115 · 3710.1016/j.jconrel.2006.07.011 ↗
27. Manickam · Bioconjug. Chem. · 2006 · 17 · 139510.1021/bc060104k ↗
28. Peng · Acta Biomater. · 2020 · 105 · 22310.1016/j.actbio.2020.01.005 ↗
29. Son · Adv. Drug Deliv. Rev. · 2019 · 138 · 13310.1016/j.addr.2018.10.002 ↗